Dihydroartemisinin with minoxidil for female androgenetic alopecia
A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Female Androgenetic Alopecia
This trial will test whether taking oral dihydroartemisinin along with topical minoxidil helps increase terminal hairs on the top of the head in adult women with androgenetic alopecia.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | Shanghai Zhongshan Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT07012486 on ClinicalTrials.gov |
What this trial studies
Adult women with clinically diagnosed androgenetic alopecia will receive either daily oral dihydroartemisinin plus topical 5% minoxidil or topical 5% minoxidil alone for six months. Participants will attend the clinic once monthly for checkups and tests. The main outcome is change in terminal hair follicles in the vertex (top) scalp area. The comparison aims to determine whether adding dihydroartemisinin improves hair growth beyond minoxidil alone.
Who should consider this trial
Good fit: Adult women with clinically diagnosed androgenetic alopecia who are not planning pregnancy within six months and meet the study's safety criteria are ideal candidates.
Not a fit: Patients who are pregnant or breastfeeding, have recent use of systemic or topical hair-loss drugs, or have severe organ disease or malignancy may not benefit or be eligible.
Why it matters
Potential benefit: If successful, adding dihydroartemisinin could increase visible hair density on the scalp compared with minoxidil alone.
How similar studies have performed: Using dihydroartemisinin for hair loss is largely novel with limited prior clinical evidence in humans.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically diagnosed with androgenetic alopecia (AGA) * No pregnancy plans within the next 6 months Exclusion Criteria: * Patients who received systemic medications for hair loss within the past 2 months * Use of topical medication for hair loss within the past 2 weeks * Pregnancy or lactation * Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Where this trial is running
Shanghai, Shanghai Municipality
- Zhongshan Hospital Fudan University — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Principal investigator: Jingjing JIANG, MD, PhD — Fudan University
- Study coordinator: Lujuan GAO, MD, PhD
- Email: gao.lujuan@zs-hospital.sh.cn
- Phone: 86-021-64041990
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.